M Carroll, S Kingsman… - US Patent …, 2011 - freepatentsonline.com There is provided an MHC class I peptide epitope from 5T4 antigen. In particular, there is provided a peptide epitope of 5T4 which comprises one of the following: (i) the amino acid sequence shown as SEQ ID NO: 2; (ii) the minimal epitope from the amino acid sequence shown as SEQ ID ... Cached - All 2 versions
[HTML] from nih.govSK Watkins, Z Zhu, E Riboldi… - The Journal of clinical …, 2011 - ncbi.nlm.nih.gov ... The limited success of cancer immunotherapy is often attributed to the loss of antigen-specific T cell function in situ. However, the mechanism for this loss of function is unknown. In this study, we describe a population of tumor-associated DCs (TADCs) in both human and mouse ... Cited by 4 - Related articles - All 4 versions
[HTML] from hematologylibrary.orgC Pospori, SA Xue, A Holler… - …, 2011 - bloodjournal.hematologylibrary.org Recently, vaccines against the Wilms Tumor antigen 1 (WT1) have been tested in cancer patients. However, it is currently not known whether physiologic levels of WT1 expression in stem and progenitor cells of normal tissue result in the deletion or tolerance induction of ... Cited by 1 - Related articles - All 3 versions
[PDF] from oncimmune.comA Murray, S Storr, L Bottomley… - American Journal of …, 2011 - oncimmune.com ...Tumor-AssociatedAntigens Andrea Murray1, Sarah Storr1, Laura Bottomley1, Jane McElveen1, Celine Parsy-Kowalska1, Caroline Chapman2 and John Robertson2 ... tumor-associatedantigens in lung cancer. Since such autoantibodies may ... View as HTML - All 4 versions
[PDF] from hindawi.comJ Luka, PM Arlen… - Journal of Biomedicine and …, 2011 - downloads.hindawi.com ... NPC-1 is a monoclonal antibody that was derived from a TumorAssociatedAntigen- (TAA-) based vaccine that was previously tested in Phase I-II clinical trials performed in the United States [7–9]. The TAA utilized in these studies was derived from pooled allogeneic colon ... Related articles - View as HTML - All 6 versions